正文
Dr. Philip D. Bonomi currently serves as professor of Medical Oncology and Internal Medicine at the Rush University Medical Center in Chicago. The acclaimed institution has consistently been ranked among the best hospitals in the Unites States and was most recently awarded a top 50 ranking in 11 of 16 care categories.
He completed his medical degree at the University of Illinois College of Medicine at Chicago. He then completed his residency program Geisinger Medical Center in the field of internal medicine. Dr. Bonomi joined Rush University Medical Center by completing a fellowship in medical oncology.
Dr. Bonomi’s primary area of interest is within the field of thoracic and cardiothoracic oncology, with his specialties being in lung cancer and mesothelioma. The majority of Dr. Bonomi’s research interest is in the field of lung cancer treatment and detection. What’s more, he has also authored or co-authored over 150 publications, primarily in the field of small-cell lung cancer detection and survival-rate improvements. He is a member of the International Association for the Study of Lung Cancer. With over three decades of experience in the field of lung cancer research, he has served as the Chairman of the Thoracic Committee for the Eastern Cooperative Oncology Group. His most research has centered on the study of new chemotherapeutic agents for multi-modality therapies in the treatment of small-cell lung cancer.
作为一名享誉全球的肺癌肿瘤学家，尤其在肺上沟瘤的治疗中，Philip Bonomi教授认为，如果肺上沟瘤仅扩散到上沟，并没有到纵隔淋巴结，治愈率是相当高的。标准疗法是术后联合使用顺铂，依托泊苷治疗和放疗，将会有接近50％的治愈机会。唯一不足的是，这类特殊肿瘤的患病群体数目较小，目前还没有随机研究来证明这是最好的治疗方法。其次，鉴于其位置和分期的特殊性，往往很难被诊断出来。大多时候人们会因为肩膀疼痛去看医生，但事实上癌细胞已经在影响你的臂丛，给你带来疼痛。因此，治疗的关键在于早诊断，防止癌细胞扩散到纵膈淋巴结和其他部位。
